摘要
目的 了解血浆脑源性神经营养因子（BDNF）、血管内皮细胞生长因子（VEGF）在多发性骨髓瘤（MM）病人中的含量，并探讨其在MM发病中的作用。方法 用酶联免疫吸附试验（ELISA）方法，测定20例正常人（正常对照组）与56例MM病人血浆BDNF、VEGF的水平，并对不同免疫亚型、不同临床分期、治疗前后检测结果进行比较。结果治疗前MM病人血浆BDNF、VEGF水平明显高于正常对照组，差异有显著性（t=15．859、13．517，P〈0．001）。治疗有效的44例MM病人血浆BDNF、VEGF水平较治疗前明显下降，差异有显著性（t=12．35、10．26，P〈0．01）；治疗无效的10例MM病人治疗前后血浆BDNF、VEGF水平无明显差异（t=1．56、1．78，P〉0．05）。不同临床分期MM病人之间血浆BDNF、VEGF水平比较差异有显著性（F=4．63、4、10，P〈0．05），Ⅲ 期病人血浆BDNF、VEGF水平明显高于Ⅰ期病人（q=3．86～3．90，P〈0．05）。但MM病人不同免疫亚型之间血浆BDNF、VEGF水平无统计学差异（F=1.49、1.31，P〉0．05）。结论 血浆BDNF、VEGF水平在MM病人呈高表达，并且与其临床分期有关，可作为MM疗效判断的一个辅助指标。
Objective To investigate the plasma concentrations of brain-derived neurotrophic factor （BDNF） and vascular endothelial growth factor （VEGF） in patients with multiple myeloma （MM）, and to explore their relationship with the pathogenesis of the disease. Methods Plasma concentrations of BDNF and VEGF in MM patients （n = 56） and controls （n = 20） were evaluated by ELISA. A comparison was made in terms of different immune-subtypes, different clinical stages, BDNF and VEGF levels before and after treatment between the two groups. Results Plasma BDNF and VEGF in patients before treatment were markedly higher than that in the controls （t = 15.859,13.517 ; P〈0.001 ）. Of 44 patients who showed response to the therapy, the BDNF and VEGF declined after the treatment （t=12.35,10.26;P〈0.01）. For 10 patients who did not response to the therapy, the difference of BDNF and VEGF before and after the therapy was not significant （t= 1.56,1.78; P〉0.05）. The differences of BDNF and VEGF in patients of different stages were significant （F= 4. 63,4. 10; P〈 0. 05）. The levels of BDNF and VEGF in stage-Ⅲ patients were higher than those of stage- [ patients （q= 3.86- 3.90, P〈0.05）. No significant difference in levels of BDNF and VEGF was noted among the three immune-subtypes of MM （F= 1.49,1.31; P〉0. 05）. Conclusion The high expression of plasma BDNF and VEGF is seen in patients with multiple myeloma, and it is related with different clinical stages, which could serve as helpful indexes to evaluate the therapeutic efficacy for the disease.
出处
《齐鲁医学杂志》
2007年第2期128-130,共3页
Medical Journal of Qilu
